Roivant Sciences Ltd. (ROIV)
After hours:
| Previous close | 6.98 |
| Open | 6.84 |
| Bid | 6.45 x 1800 |
| Ask | 7.09 x 2200 |
| Day's range | 6.83 - 7.11 |
| 52-week range | 2.52 - 16.76 |
| Volume | |
| Avg. volume | 1,417,357 |
| Market cap | 5.078B |
| Beta (5Y monthly) | 1.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.52 |
| Earnings date | 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.25 |
- GlobeNewswire
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase 2b study (TUSCANY-2) with final results expected in 1H 2023 BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PF
- GlobeNewswire
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
Expected cash runway extended into the second half of calendar year 2025First major PBM/payer contract signed for VTAMA, effective October 1Over 54,000 VTAMA prescriptions written by approximately 6,400 prescribers since launch show strong demand, with fiscal Q2 2022 net product revenue of $5.0 millionUnveiled IMVT-1402, a next generation anti-FcRn which showed deep IgG lowering similar to batoclimab with no or minimal impact observed on albumin and LDL (low-density lipoprotein) levels in animal
- GlobeNewswire
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32). AFVT-2101 is a tetravalent, bispecific Innate Cell Engager (ICE®) that bridges folate receptor alpha (FRα) on tumo
